Literature DB >> 8741229

The importance of dopamine D4 receptors in the action and development of antipsychotic agents.

G P Reynolds1.   

Abstract

The dopamine D4 receptor, recently identified by molecular biological techniques, is expressed in areas of the brain implicated in the pathophysiology of schizophrenia. Although it has a lower affinity than the D2 receptor for most antipsychotic drugs, the D4 receptor has a higher affinity for clozapine, which may explain the unique efficacy of clozapine in the treatment of schizophrenia. However, there is no association between genetic alterations of the D4 gene and either the development of schizophrenia or response to clozapine administration, nor is the absence of the receptor related to major neuropsychiatric deficits. The report of an increase in D4 receptor density in the striatum in schizophrenia has not been consistently confirmed. Thus, it appears that there is little to support the development of D4 antagonists as potential antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8741229     DOI: 10.2165/00003495-199651010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  34 in total

1.  Dopamine D4 receptor polymorphism and schizophrenia.

Authors:  S Nanko; M Hattori; K Ikeda; T Sasaki; H Kazamatsuri; S Kuwata
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

Review 2.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-08

3.  Dopamine D4 receptor variants in unrelated schizophrenic cases and controls.

Authors:  S S Sommer; T J Lind; L L Heston; J L Sobell
Journal:  Am J Med Genet       Date:  1993-07-15

4.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

5.  Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.

Authors:  A M Murray; T M Hyde; M B Knable; M M Herman; L B Bigelow; J M Carter; D R Weinberger; J E Kleinman
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

6.  Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia.

Authors:  G P Reynolds; S L Mason
Journal:  Eur J Pharmacol       Date:  1995-08-04       Impact factor: 4.432

7.  D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.

Authors:  L S Pilowsky; D C Costa; P J Ell; N P Verhoeff; R M Murray; R W Kerwin
Journal:  Br J Psychiatry       Date:  1994-01       Impact factor: 9.319

8.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

9.  Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors.

Authors:  K Hidaka; M Matsumoto; S Tada; Y Tasaki; T Yamaguchi
Journal:  Neurosci Lett       Date:  1995-02-17       Impact factor: 3.046

10.  Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred.

Authors:  F Macciardi; A Petronis; H H Van Tol; C Marino; M C Cavallini; E Smeraldi; J L Kennedy
Journal:  Arch Gen Psychiatry       Date:  1994-04
View more
  2 in total

1.  Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.

Authors:  L Gazi; I Bobirnac; M Danzeisen; E Schüpbach; D Langenegger; B Sommer; D Hoyer; M Tricklebank; P Schoeffter
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia.

Authors:  Atsuhiro Miyazawa; Nobuhisa Kanahara; Yusuke Nakata; Satoshi Kodama; Hiroshi Kimura; Atsushi Kimura; Yasunori Oda; Hiroyuki Watanabe; Masaomi Iyo
Journal:  Psychopharmacol Bull       Date:  2021-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.